Oncotelic Therapeutics (OTLC) Common Equity (2010 - 2026)
Oncotelic Therapeutics (OTLC) recorded Common Equity of $264.56 million in Q2 2026, compared with $7.39 million a year earlier.
Powered by 
Analysis
Oncotelic Therapeutics (OTLC) Common Equity (2010 - 2026) Analysis & Trends
At the end of FY2025, Oncotelic Therapeutics reported Common Equity of $262.76 million.
- Annual Common Equity has a five-year compound annual growth rate of 83.9% (FY2020 to FY2025).
- Across earlier years, Common Equity came in at $7.48 million in FY2024 (-35.6%), $11.61 million in FY2023 (-39.5%), $19.19 million in FY2022 (+135.3%) and $8.16 million in FY2021 (-34.6%).
- The Q2 2026 figure is the highest quarterly Common Equity in data going back to Q4 2010.
- On a year-over-year basis, Common Equity rose in 1 of the last five quarters, with an average decline of 25.8%.
- Peak year-over-year performance for Common Equity in the last five years was growth of 191.8% in Q1 2023, against a decline of 50.9% in Q2 2023 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 33.88 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 84.97 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | -5.94 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 41.98 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 41.95 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 50.37 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 11.69 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 11.83 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 85.49 Bn |
| 10 | Oncotelic Therapeutics | 8.46 Mn | 7.60 Mn | - | 264.56 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 264.56 Mn |
| Dec 31, 2025 | 262.76 Mn |
| Sep 30, 2025 | 9.05 Mn |
| Jun 30, 2025 | 7.39 Mn |
| Mar 31, 2025 | 7.18 Mn |
| Dec 31, 2024 | 7.48 Mn |
| Sep 30, 2024 | 8.13 Mn |
| Jun 30, 2024 | 11.50 Mn |
| Mar 31, 2024 | 11.25 Mn |
| Dec 31, 2023 | 11.61 Mn |
| Sep 30, 2023 | 12.09 Mn |
| Jun 30, 2023 | 11.93 Mn |
| Mar 31, 2023 | 18.45 Mn |
| Dec 31, 2022 | 19.19 Mn |
| Sep 30, 2022 | 24.03 Mn |
| Jun 30, 2022 | 24.28 Mn |
| Mar 31, 2022 | 6.32 Mn |
| Dec 31, 2021 | 8.16 Mn |
| Sep 30, 2021 | 8.39 Mn |
| Jun 30, 2021 | 9.59 Mn |
API Access
Oncotelic Therapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=OTLC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "OTLC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=OTLC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();